Asset Type: Media article

New technologies that help drive the blistering pace of discovery in biology were highlighted by a panel of experts Wednesday in a “top ten” list of game-changing innovations.

As Pacific Biosciences is shipping its first sequencing instruments to beta customers – as of earlier this month, it had installed them at eight sites – the company has been testing its real-time single-molecule technology for a variety of applications, both in DNA sequencing and other areas.

The Great Beyond. The Smithsonian Air and Space Museum was the place to be yesterday evening for conference-goers at the American Society of Human Genetic meeting in Washington DC. The gene sequencing company Pacific Biosciences had taken over the museum for a premier screening of a documentary film the company had made called “The..

In October 2008, Fortune magazine called Pacific Biosciences of California Inc. “Silicon Valley’s hottest startup.” Almost exactly two years later, the Menlo Park biotech company has ditched its training wheels and gone public, in a very healthy way.

The Pacific Biosciences IPO was an important deal yesterday for more reasons than one.

Pacific Biosciences, a maker of DNA sequencing machines, goes public today with a $200 million initial public offering.

Edenvale Technology Park gives a glimpse of the new Silicon Valley.

When Hugh Martin learned he had cancer, he did the unimaginable. He revealed everything.

The world is still dealing with the effects of a severe economic crisis. But judging from the results of this year’s Wall Street Journal Technology Innovation Awards, there’s no crisis in tech innovation.

Pacific Biosciences single molecule, real-time sequencer RS expected to be installed in Konstanz in early 2011

Scientists aim to monitor communities for infections using fast sequencing technology.

SAIC will use GeneSifter Lab Edition to create workflows and data-analysis methods that are “unique” to PacBio’s SMRT sequencer, as well as additional functionalities that will tailor the system to researchers’ needs.

Gene sequencing instrument providers are currently at the center of a range of corporate activities: acquisition, partnering, financing.

To make the most of new technologies, medicine must come to grips with the mountains of data it will produce.

Another milestone in the hot business of decoding DNA molecules: Menlo Park, Calif.-based Pacific Biosciences has filed for a $200 million initial public offering.